{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:54:04Z","timestamp":1793393644308,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","aaojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ophtha.2024.03.012","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T07:51:06Z","timestamp":1710402666000},"page":"1045-1055","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["An Evaluation of the Efficacy and Safety of Timolol Maleate 0.5% Microdrops Administered with the Nanodropper"],"prefix":"10.1016","volume":"131","author":[{"given":"Jennifer S.","family":"Steger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indira","family":"Durai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamalai","family":"Odayappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramalakshmi","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talla","family":"Sruthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allisa J.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Puthuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rengaraj","family":"Venkatesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Colantuoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1959-8770","authenticated-orcid":false,"given":"Alan L.","family":"Robin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2024.03.012_bib1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S2214-109X(20)30425-3","article-title":"Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study","volume":"9","author":"Bourne","year":"2021","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.ophtha.2024.03.012_bib2","doi-asserted-by":"crossref","first-page":"P71","DOI":"10.1016\/j.ophtha.2020.10.022","article-title":"Primary open-angle glaucoma preferred practice pattern\u00ae","volume":"128","author":"Gedde","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2024.03.012_bib3","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1016\/j.ophtha.2011.05.013","article-title":"The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity","volume":"118","author":"Sleath","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2024.03.012_bib4","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ophtha.2019.10.022","article-title":"The association between medication adherence and visual field progression in the collaborative initial glaucoma treatment study","volume":"127","author":"Newman-Casey","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2024.03.012_bib5","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ophtha.2004.12.035","article-title":"Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review","volume":"112","author":"Olthoff","year":"2005","journal-title":"Ophthalmology"},{"issue":"Suppl 1","key":"10.1016\/j.ophtha.2024.03.012_bib6","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.survophthal.2008.08.002","article-title":"Adherence and persistence with glaucoma therapy","volume":"53","author":"Schwartz","year":"2008","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.03.012_bib7","first-page":"514","article-title":"Adherence to therapy in glaucoma treatment\u2014a review","volume":"12","author":"Zaharia","year":"2022","journal-title":"J\u00a0Pers Med"},{"key":"10.1016\/j.ophtha.2024.03.012_bib8","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ophtha.2023.12.022","article-title":"The effect of insurance coverage laws on glaucoma eyedrop medication usage","volume":"131","author":"Hehr","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2024.03.012_bib9","first-page":"18","article-title":"Noncompliance with prescribed eyedrop regimens among patients undergoing cataract surgery\u2014prevalence, consequences, and solutions","volume":"13","author":"Matossian","year":"2020","journal-title":"US Ophthalmic Rev"},{"key":"10.1016\/j.ophtha.2024.03.012_bib10","first-page":"367","article-title":"Adherence to eye drops usage in dry eye patients and reasons for non-compliance: a web-based survey","volume":"11","author":"Uchino","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.ophtha.2024.03.012_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2415-14-79","article-title":"Prevalence of self-reported early glaucoma eye drop bottle exhaustion and associated risk factors: a patient survey","volume":"14","author":"Moore","year":"2014","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.03.012_bib13","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/0002-9394(78)90129-0","article-title":"Use of dilute drug solutions for routine cycloplegia and mydriasis","volume":"86","author":"Brown","year":"1978","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.03.012_bib14","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/archopht.1980.01020030114010","article-title":"Topically applied pilocarpine: human pupillary response as a function of drop size","volume":"98","author":"File","year":"1980","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.03.012_bib15","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/bjo.75.4.222","article-title":"Effect on mydriasis of modifying the volume of phenylephrine drops","volume":"75","author":"Craig","year":"1991","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.03.012_bib16","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/eye.1991.107","article-title":"The influence of drop size on pupil dilatation","volume":"5","author":"Gray","year":"1991","journal-title":"Eye"},{"key":"10.1016\/j.ophtha.2024.03.012_bib17","article-title":"The influence of drop size of tropicamide 0,5% eye drops on pupil dilation","volume":"57","author":"Van Der Heiden","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2024.03.012_bib18","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0002-9394(14)71527-2","article-title":"Reformulation and drop size of apraclonidine hydrochloride","volume":"113","author":"Vocci","year":"1992","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.03.012_bib19","first-page":"267","article-title":"Pharmacodynamic effects of pilocarpine eye drop enhanced by decreasing its volume of instillation","volume":"39","author":"Lal","year":"1995","journal-title":"Indian J Physiol Pharmacol"},{"key":"10.1016\/j.ophtha.2024.03.012_bib20","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/106002809002400421","article-title":"Drop size and systemic adverse effects in timolol ophthalmic solution","volume":"24","author":"Montoro","year":"1990","journal-title":"DICP"},{"key":"10.1016\/j.ophtha.2024.03.012_bib21","first-page":"351","article-title":"Effect of varying drop size on the efficacy and safety of a topical beta blocker","volume":"21","author":"Charap","year":"1989","journal-title":"Ann Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.03.012_bib22","first-page":"264","article-title":"Determination of tear volume and tear flow","volume":"5","author":"Mishima","year":"1966","journal-title":"Invest Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.03.012_bib23","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0002-9394(86)90771-3","article-title":"Drop size of commercial glaucoma medications","volume":"101","author":"Lederer","year":"1986","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.03.012_bib24","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/jps.2600620712","article-title":"Lacrimal and instilled fluid dynamics in rabbit eyes","volume":"62","author":"Chrai","year":"1973","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.ophtha.2024.03.012_bib25","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2165\/00003088-199529020-00006","article-title":"Clinical pharmacokinetics of various topical ophthalmic delivery systems","volume":"29","author":"Frangie","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ophtha.2024.03.012_bib26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/jop.1987.3.177","article-title":"Systemic side effects from ophthalmic timolol and their prevention","volume":"3","author":"Fraunfelder","year":"1987","journal-title":"J\u00a0Ocul Pharmacol"},{"key":"10.1016\/j.ophtha.2024.03.012_bib27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0039-6257(82)90081-9","article-title":"Pharmacokinetics of topically applied ophthalmic drugs","volume":"26","author":"Shell","year":"1982","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.03.012_bib28","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0039-6257(93)90141-S","article-title":"Minimizing systemic absorption of topically administered ophthalmic drugs","volume":"37","author":"Urtti","year":"1993","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.03.012_bib29","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1345\/aph.18464","article-title":"Systemic adverse effects of ophthalmic \u03b2-blockers","volume":"35","author":"Vander Zanden","year":"2001","journal-title":"Ann. Pharmacother"},{"key":"10.1016\/j.ophtha.2024.03.012_bib30","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2147\/OPTH.S44708","article-title":"Managing adverse effects of glaucoma medications","volume":"8","author":"Inoue","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.03.012_bib31","article-title":"Ophthalmic timolol and hospitalization for symptomatic bradycardia and syncope: a case series","volume":"12","author":"Abbas","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.ophtha.2024.03.012_bib32","doi-asserted-by":"crossref","first-page":"192","DOI":"10.4103\/2231-4040.85540","article-title":"Reduction in drop size of ophthalmic topical drop preparations and the impact of treatment","volume":"2","author":"Kumar","year":"2011","journal-title":"J\u00a0Adv Pharm Technol Res"},{"key":"10.1016\/j.ophtha.2024.03.012_bib33","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/archopht.1984.01040030958024","article-title":"Treatment of glaucoma using minidrops of clonidine","volume":"102","author":"Petursson","year":"1984","journal-title":"Arch Ophthalmol"},{"issue":"Suppl","key":"10.1016\/j.ophtha.2024.03.012_bib34","first-page":"161","article-title":"Does drop size influence the efficacy of a topical beta blocker?","volume":"27","author":"Miller","year":"1986","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2024.03.012_bib35","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1001\/archopht.1987.01060100066027","article-title":"Reduction of phenylephrine drop size in infants achieves equal dilation with decreased systemic absorption","volume":"105","author":"Lynch","year":"1987","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.03.012_bib36","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0161-6420(87)33538-9","article-title":"Improving the therapeutic index of topical phenylephrine by reducing drop volume","volume":"94","author":"Brown","year":"1987","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2024.03.012_bib37","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.2042-7158.1992.tb05495.x","article-title":"Visual recovery using small dilating eye drops","volume":"44","author":"Gray","year":"1992","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.ophtha.2024.03.012_bib38","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0002-9394(14)73588-3","article-title":"The effect of reduced eyedrop size and eyelid closure on the therapeutic index of phenylephrine","volume":"115","author":"Whitson","year":"1993","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.03.012_bib39","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1600-0420.1997.tb00119.x","article-title":"The influence of drop size of cyclopentolate, phenylephrine and tropicamide on pupil dilatation and systemic side effects in infants","volume":"75","author":"Elibol","year":"1997","journal-title":"Acta Opthalmologica Scandinav"},{"key":"10.1016\/j.ophtha.2024.03.012_bib40","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41372-021-01229-w","article-title":"Efficacy and safety of mydriatic microdrops for retinopathy of prematurity screening: an external pilot crossover randomized controlled trial","volume":"42","author":"Seliniotaki","year":"2022","journal-title":"J\u00a0Perinatol"},{"key":"10.1016\/j.ophtha.2024.03.012_bib41","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ophtha.2022.10.016","article-title":"Randomized trial to evaluate the efficacy of the Nanodropper device for pupillary dilation and cycloplegia in children","volume":"130","author":"Hoppe","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2024.03.012_bib42","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/bjo.77.6.364","article-title":"Reduction in mydriatic drop size in premature infants","volume":"77","author":"Wheatcroft","year":"1993","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.03.012_bib43","author":"Hendricks","year":"1997","journal-title":"Mydriatics: drop the dose, Pacific University College of Optometry Theses, Dissertations and Capstone Projects"},{"key":"10.1016\/j.ophtha.2024.03.012_bib44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4155\/tde-2017-0095","article-title":"High-precision piezo-ejection ocular microdosing: Phase II study on local and systemic effects of topical phenylephrine","volume":"9","author":"Ianchulev","year":"2018","journal-title":"Ther Deliv"},{"key":"10.1016\/j.ophtha.2024.03.012_bib45","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.2147\/OPTH.S185027","article-title":"Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 \u03bcg daily microdose","volume":"12","author":"Pasquale","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.03.012_bib46","first-page":"71","article-title":"Reduction of eyedrop volume for topical ophthalmic medications with the Nanodropper bottle adaptor","volume":"16","author":"St Peter","year":"2023","journal-title":"Med Devices (Auckl)"},{"key":"10.1016\/j.ophtha.2024.03.012_bib48","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1755-3768.2007.01159.x","article-title":"Mean standard deviations for common glaucoma treatments","volume":"87","author":"Stewart","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.03.012_bib49","series-title":"Applied Longitudinal Analysis","first-page":"124","article-title":"Section 5.6: Adjustment for baseline response and section","author":"Fitzmaurice","year":"2011"},{"key":"10.1016\/j.ophtha.2024.03.012_bib50","series-title":"Applied Longitudinal Analysis","first-page":"128","article-title":"Section 5.7: Alternative methods of adjusting for baseline response","author":"Fitzmaurice","year":"2011"},{"key":"10.1016\/j.ophtha.2024.03.012_bib51","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1177\/009127009703700110","article-title":"Temporal variation in the effects of ophthalmic timolol on cardiovascular and respiratory functions in healthy men","volume":"37","author":"Umetsuki","year":"1997","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.ophtha.2024.03.012_bib52","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.2147\/OPTH.S87988","article-title":"The intraocular pressure-lowering properties of intravenous paracetamol","volume":"10","author":"van den Heever","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.03.012_bib53","first-page":"489","article-title":"Intraocular pressure decrease in normal volunteers following timolol ophthalmic solution","volume":"15","author":"Katz","year":"1976","journal-title":"Invest Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.03.012_bib54","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/archopht.1977.04450040071009","article-title":"Timolol: dose response and duration of action","volume":"95","author":"Zimmerman","year":"1977","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.03.012_bib55","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s00417-002-0462-2","article-title":"Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops","volume":"240","author":"Korte","year":"2002","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.03.012_bib56","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/archopht.1995.01100010079024","article-title":"The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine","volume":"113","author":"Nordlund","year":"1995","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.03.012_bib57","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/jps.2600630304","article-title":"Drop size and initial dosing frequency problems of topically applied ophthalmic drugs","volume":"63","author":"Chrai","year":"1974","journal-title":"J\u00a0Pharm Sci"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642024001891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642024001891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T08:12:26Z","timestamp":1728547946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642024001891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0161642024001891"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2024.03.012","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Evaluation of the Efficacy and Safety of Timolol Maleate 0.5% Microdrops Administered with the Nanodropper","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2024.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}]}}